The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf of investors who purchased Athira Pharma, Inc. (NASDAQ: ATHA) between September 18, 2020 and June 17, 2021 and/or purchased common stock in or traceable to the Company’s registration statement issued in connection with the Company’s September 2020 initial public offering priced at $17.00 per share.
According to the Athira Pharma lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the research conducted by Defendant Kawas, which formed the foundation for Athira’s product candidates and intellectual property, was tainted by Kawas’ scientific misconduct, including the manipulation of key data through the altering of Western blot images; and (2) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and omitted material facts necessary in order to make the statements made not misleading.
If you suffered a loss in Athira Pharma you have until August 24, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
To receive more information, please fill out the form.